- NCT00210782
- Primary Citation
- Data Specification Not Available
Trial Information
Generic NameTopiramateProduct NameTOPAMAX®Therapeutic AreaNervous System DiseasesEnrollment262% Female51.7%% White63.3%
Product ClassAnticonvulsantsSponsor Protocol NumberCAPSS-272Data PartnerJohnson & JohnsonCondition StudiedEpilepsyMean/Median Age (Years)34.2
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2021-4712 : Real time monitoring of individual response to antiseizure medication treatment during clinical trials
- 2020-4276 : Psychiatric Symptoms as Adverse Events of Topiramate Therapy: Systematic Review and Meta-Analysis
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.